Scott Minick served as President and Chief Executive Officer of BIND Therapeutics, a biopharmaceutical company (NASDAQ: BIND), from 2010 to 2015. From 1998 to 2010, he was Managing Director of ARCH Venture Partners, a leading venture capital firm, and was instrumental in the startup, development and financing of numerous ARCH biotechnology portfolio companies, including BIND, Chiasma (NASDAQ: CHMA) and Xenoport (NASDAQ: XNPT). From 1995 to 1998, Minick was Director, President and Chief Operating Officer of SEQUUS Pharmaceuticals, (NASDAQ:SEQU), a biopharmaceutical company that was acquired by ALZA Corporation and subsequently J&J. He was formerly an executive at Baxter International, Inc. and Eli Lilly & Company. He currently serves as a member of the board of directors of Chiasma and Alzheon.
Minick has also been active in not-for-profit organizations including serving as a Director of California Pacific Medical Center, including Chairman of the Board, Trustee of Beth Israel Deaconess Medical Center (a Harvard teaching hospital), Director of NatureBridge, a member of the Dean’s Advisory Board at Northwestern University’s Kellogg School of Management, the advisory board of INVO at Northwestern University, the Technology Transfer Advisory Council or UCSD and a Trustee of Ross School.
He received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University, and a Bachelor of Arts from the University of California, San Diego.